{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:05:14Z","timestamp":1787673914069,"version":"build-2784847793"},"reference-count":324,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.semcancer.2025.01.007","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:50:14Z","timestamp":1739001014000},"page":"16-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies"],"prefix":"10.1016","volume":"111","author":[{"given":"Daosong","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2025.01.007_bib1","doi-asserted-by":"crossref","first-page":"1343512","DOI":"10.3389\/fimmu.2024.1343512","article-title":"Unraveling the causal role of immune cells in gastrointestinal tract cancers: insights from a Mendelian randomization study","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib2","article-title":"Gastric cancer: a comprehensive literature review","volume":"16","author":"Mithany","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.semcancer.2025.01.007_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000443995","article-title":"Etiology and prevention of gastric cancer","volume":"3","author":"Cheng","year":"2016","journal-title":"Gastrointest. Tumors"},{"key":"10.1016\/j.semcancer.2025.01.007_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/postgradmedj-2016-133997","article-title":"Gastric adenocarcinoma: the role of Helicobacter pylori in pathogenesis and prevention efforts","volume":"92","author":"Laird-Fick","year":"2016","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.semcancer.2025.01.007_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/diseases10030035","article-title":"Inflammation and gastric cancer","volume":"10","author":"Jaroenlapnopparat","year":"2022","journal-title":"Diseases"},{"key":"10.1016\/j.semcancer.2025.01.007_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori","volume":"136","author":"Plummer","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib7","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA: a Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2025.01.007_bib8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular senescence: defining a path forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib9","series-title":"Seminars in oncology","first-page":"206","article-title":"R.J. Mayer, Gastrointestinal cancer in older patients","author":"Enzinger","year":"2004"},{"key":"10.1016\/j.semcancer.2025.01.007_bib10","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.semcancer.2025.01.007_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: a key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging: an evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-019-0804-8","article-title":"Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment","volume":"12","author":"Yang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib15","article-title":"Tumor microenvironment diversity and plasticity in cancer multidrug resistance","volume":"1878","author":"Li","year":"2023","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Rev. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib16","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3748\/wjg.v20.i7.1657","article-title":"D.Y. Graham, Immunotherapy in gastric cancer","volume":"20","author":"Matsueda","year":"2014","journal-title":"World J. Gastroenterol.: WJG"},{"key":"10.1016\/j.semcancer.2025.01.007_bib17","first-page":"1","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Immunol. Asp. Neoplasia"},{"key":"10.1016\/j.semcancer.2025.01.007_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2025.01.007_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2010.02.006","article-title":"Natural immunity to cancer in humans","volume":"22","author":"Bindea","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib20","series-title":"Helper T cells and lymphocyte activation, Molecular biology of the cell","author":"Alberts","year":"2002"},{"key":"10.1016\/j.semcancer.2025.01.007_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101435","article-title":"Memory CD8+ T cell responses to cancer","volume":"49","author":"Han","year":"2020","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ni.2050","article-title":"Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells","volume":"12","author":"Thiery","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.1258867","article-title":"A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection","volume":"348","author":"Deng","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2025.01.007_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/geront\/4.4.195","article-title":"The immunologic theory of aging","volume":"4","author":"Walford","year":"1964","journal-title":"Gerontologist"},{"key":"10.1016\/j.semcancer.2025.01.007_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cger.2011.07.001","article-title":"Theories and mechanisms of aging","volume":"27","author":"Cefalu","year":"2011","journal-title":"Clin. Geriatr. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib27","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1073\/pnas.1714478115","article-title":"Thymic involution and rising disease incidence with age","volume":"115","author":"Palmer","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12979-020-0173-8","article-title":"Contributions of age-related thymic involution to immunosenescence and inflammaging","volume":"17","author":"Thomas","year":"2020","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.semcancer.2025.01.007_bib29","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.4049\/jimmunol.1301721","article-title":"Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans","volume":"192","author":"Wertheimer","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.it.2009.04.003","article-title":"Thymic involution and immune reconstitution","volume":"30","author":"Lynch","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1172\/JCI7558","article-title":"Analysis of the human thymic perivascular space during aging","volume":"104","author":"Flores","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.semcancer.2025.01.007_bib32","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","article-title":"Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes?","volume":"8","author":"Fulop","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.0105-2896.2005.00259.x","article-title":"The role of CD8+ T-cell replicative senescence in human aging","volume":"205","author":"Effros","year":"2005","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"key":"10.1016\/j.semcancer.2025.01.007_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12307-011-0069-4","article-title":"Epithelial-mesenchymal transition induced by senescent fibroblasts","volume":"5","author":"Laberge","year":"2012","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.semcancer.2025.01.007_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2019.04.002","article-title":"Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer","volume":"454","author":"Zhai","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2025.01.007_bib37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0002-9343(03)00329-2","article-title":"Elevated levels of tumor necrosis factor alpha and mortality in centenarians","volume":"115","author":"Bruunsgaard","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev.med.51.1.245","article-title":"Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty","volume":"51","author":"Ershler","year":"2000","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-016-0076-x","article-title":"Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study","volume":"13","author":"Puzianowska-Ku\u017anicka","year":"2016","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.semcancer.2025.01.007_bib40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.virol.2004.11.028","article-title":"Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes","volume":"332","author":"Yang","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib41","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/nprot.2009.191","article-title":"Protocols to detect senescence-associated beta-galactosidase (SA-\u03b2gal) activity, a biomarker of senescent cells in culture and in vivo","volume":"4","author":"Debacq-Chainiaux","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.semcancer.2025.01.007_bib42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib43","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib44","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1172\/JCI75051","article-title":"p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8+\u2009T cells","volume":"124","author":"Henson","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.semcancer.2025.01.007_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.semcancer.2025.01.007_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41556-022-01053-0","article-title":"Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing","volume":"25","author":"Mitchell","year":"2023","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.immuni.2019.06.006","article-title":"Plasma cells are obligate effectors of enhanced myelopoiesis in aging bone marrow","volume":"51","author":"Pioli","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2025.01.007_bib48","first-page":"2621","article-title":"IFN-\u03b3-mediated hematopoietic cell destruction in murine models of immune-mediated bone marrow failure, Blood","volume":"126","author":"Chen","year":"2015","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.semcancer.2025.01.007_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.semcancer.2025.01.007_bib51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12943-022-01679-6","article-title":"IL-6\/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction","volume":"21","author":"Meraviglia-Crivelli","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib53","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy","volume":"12","author":"Bent","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib54","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/gutjnl-2019-319200","article-title":"STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis","volume":"69","author":"Heichler","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.semcancer.2025.01.007_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41392-022-00872-9","article-title":"Targeting polarized phenotype of microglia via IL6\/JAK2\/STAT3 signaling to reduce NSCLC brain metastasis","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.semcancer.2025.01.007_bib56","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/s41418-019-0413-7","article-title":"CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity","volume":"27","author":"Chen","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.semcancer.2025.01.007_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-018-0464-y","article-title":"IL-8\/CXCR1\/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma","volume":"25","author":"Sharma","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib58","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1084\/jem.20072509","article-title":"The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment","volume":"205","author":"Rolny","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.semcancer.2025.01.007_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661323","article-title":"Tumor NLRP3-derived IL-1\u03b2 drives the IL-6\/STAT3 axis resulting in sustained MDSC-mediated immunosuppression","volume":"12","author":"Tengesdal","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib61","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2000915118","article-title":"Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion","volume":"118","author":"Tengesdal","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib62","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41467-020-15188-x","article-title":"Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs","volume":"11","author":"Pein","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib63","doi-asserted-by":"crossref","first-page":"7619","DOI":"10.3390\/ijms21207619","article-title":"CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib64","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/0008-5472.CAN-11-2493","article-title":"Tumor-derived chemokine CCL5 enhances TGF-\u03b2\u2013mediated killing of CD8+\u2009T cells in colon cancer by T-regulatory cells","volume":"72","author":"Chang","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib65","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1158\/0008-5472.CAN-22-1890","article-title":"Stromal reprogramming through dual PDGFR\u03b1\/\u03b2 blockade boosts the efficacy of anti\u2013PD-1 immunotherapy in fibrotic tumors","volume":"83","author":"Akiyama","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib67","doi-asserted-by":"crossref","first-page":"2100712","DOI":"10.1002\/advs.202100712","article-title":"Multifunctional nanodrug mediates synergistic photodynamic therapy and MDSCs-targeting immunotherapy of colon cancer","volume":"8","author":"Ding","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib68","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/s41467-018-03966-7","article-title":"Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation","volume":"9","author":"Taki","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc2511","article-title":"Regulation of tumor immune suppression and cancer cell survival by CXCL1\/2 elevation in glioblastoma multiforme","volume":"7","author":"Hu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.semcancer.2025.01.007_bib70","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","article-title":"Type I collagen deletion in \u03b1SMA+\u2009myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-022-01357-6","article-title":"CRISPR\/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality","volume":"15","author":"Sorrentino","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib72","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1053\/j.gastro.2018.05.051","article-title":"NF\u03baB in pancreatic stellate cells reduces infiltration of tumors by cytotoxic T cells and killing of cancer cells, via up-regulation of CXCL12","volume":"155","author":"Garg","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib73","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-022-01597-7","article-title":"Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4\/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer","volume":"21","author":"Heidegger","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib74","series-title":"Seminars in Cancer Biology","first-page":"176","article-title":"The CXCL12-CXCR4\/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies","author":"Daniel","year":"2020"},{"key":"10.1016\/j.semcancer.2025.01.007_bib75","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","article-title":"TNF-\u03b1 in promotion and progression of cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastas Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib76","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190706","article-title":"The GM-CSF\u2013IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses","volume":"217","author":"Arnold","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib77","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-cellbio-011620-034148","article-title":"B cell immunosenescence","volume":"36","author":"Frasca","year":"2020","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790119","article-title":"A pan-cancer analysis of tumor-infiltrating B cell repertoires","volume":"12","author":"Yu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib79","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217341","article-title":"Functions of double-negative B cells in autoimmune diseases, infections, and cancers","volume":"15","author":"Chung","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib80","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.arr.2017.04.001","article-title":"From lymphopoiesis to plasma cells differentiation, the age-related modifications of B cell compartment are influenced by \u201cinflamm-ageing\u201d","volume":"36","author":"Bulati","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib81","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3233\/JAD-142412","article-title":"Double negative (IgG+ IgD\u2212 CD27\u2212) B cells are increased in a cohort of moderate-severe alzheimer's disease patients and show a pro-inflammatory trafficking receptor phenotype","volume":"44","author":"Bulati","year":"2015","journal-title":"J. Alzheimer'S. Dis."},{"key":"10.1016\/j.semcancer.2025.01.007_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001536","article-title":"Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity","volume":"9","author":"Gao","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib83","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/ni.2981","article-title":"The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells","volume":"15","author":"Lanna","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12675","article-title":"Human CD 8+\u2009EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK","volume":"17","author":"Callender","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib85","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.arr.2013.04.003","article-title":"The impact of ageing on natural killer cell function and potential consequences for health in older adults","volume":"12","author":"Hazeldine","year":"2013","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib86","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1474-9726.2012.00839.x","article-title":"Reduced release and binding of perforin at the immunological synapse underlies the age-related decline in natural killer cell cytotoxicity","volume":"11","author":"Hazeldine","year":"2012","journal-title":"Aging Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib87","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/acel.12303","article-title":"The aged nonhematopoietic environment impairs natural killer cell maturation and function","volume":"14","author":"Shehata","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib88","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.arr.2010.06.004","article-title":"Impact of aging on dendritic cell functions in humans","volume":"10","author":"Agrawal","year":"2011","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib89","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0047-6374(01)00270-6","article-title":"Different IL-8 production by T and NK lymphocytes in elderly subjects","volume":"122","author":"Mariani","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib90","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/1521-4141(200206)32:6<1524::AID-IMMU1524>3.0.CO;2-E","article-title":"Chemokine production by natural killer cells from nonagenarians","volume":"32","author":"Mariani","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100825","article-title":"Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1\/PD-1 axis","volume":"13","author":"Sun","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib92","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1158\/0008-5472.CAN-19-0053","article-title":"Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling","volume":"79","author":"Fleming","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib93","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4049\/jimmunol.0903670","article-title":"An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells","volume":"185","author":"Mezrich","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib94","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20020121","article-title":"Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase","volume":"196","author":"Frumento","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib95","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib96","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","article-title":"METTL3 inhibits antitumor immunity by targeting m6A-BHLHE41-CXCL1\/CXCR2 axis to promote colorectal cancer","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib97","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1038\/s41467-022-31312-5","article-title":"Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment","volume":"13","author":"Schneider","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib98","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40164-022-00334-6","article-title":"Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib99","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1016\/j.celrep.2018.11.050","article-title":"Myeloid-derived suppressor cells produce IL-10 to elicit DNMT3b-dependent IRF8 silencing to promote colitis-associated colon tumorigenesis","volume":"25","author":"Ibrahim","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2025.01.007_bib100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib101","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.arr.2017.03.008","article-title":"Aging and cancer: The role of macrophages and neutrophils","volume":"36","author":"Jackaman","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib102","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7150\/thno.37745","article-title":"Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells","volume":"10","author":"Miao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.semcancer.2025.01.007_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.902017","article-title":"Discovering immune-mediated mechanisms of gastric carcinogenesis through single-cell RNA sequencing","volume":"13","author":"Hoft","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib104","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mc.23183","article-title":"Immunogenic cell death in colon cancer prevention and therapy","volume":"59","author":"Ruan","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.semcancer.2025.01.007_bib105","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2110241118","article-title":"Colon cancer cells acquire immune regulatory molecules from tumor-infiltrating lymphocytes by trogocytosis","volume":"118","author":"Shin","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib106","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","article-title":"Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment","volume":"11","author":"Zheng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib107","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2025.01.007_bib108","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib109","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12307-011-0065-8","article-title":"Cancer-immune equilibrium: questions unanswered","volume":"4","author":"Bhatia","year":"2011","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.semcancer.2025.01.007_bib111","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance","volume":"27","author":"Campoli","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2025.01.007_bib112","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.soc.2007.08.004","article-title":"Tumor microenvironment and immune escape","volume":"16","author":"Ferrone","year":"2007","journal-title":"Surg. Oncol. Clin. North Am."},{"key":"10.1016\/j.semcancer.2025.01.007_bib113","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib114","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2025.01.007_bib115","doi-asserted-by":"crossref","first-page":"71673","DOI":"10.18632\/oncotarget.12317","article-title":"IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma","volume":"7","author":"Qi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2025.01.007_bib116","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","article-title":"Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy","volume":"42","author":"Sica","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib117","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1158\/1078-0432.CCR-13-3049","article-title":"A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response","volume":"20","author":"Busuttil","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib118","first-page":"1","article-title":"Tumor associated macrophage: a review on the phenotypes, traits and functions","volume":"7","author":"Ramanathan","year":"2014","journal-title":"Iran. J. Cancer Prev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib119","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccr.2014.03.021","article-title":"A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis","volume":"25","author":"Su","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.it.2012.08.005","article-title":"Basic principles of tumor-associated regulatory T cell biology","volume":"34","author":"Savage","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib121","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.semcancer.2025.01.007_bib122","first-page":"1291","article-title":"B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance","volume":"116","author":"Park","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib123","article-title":"Unraveling the causal role of immune cells in gastrointestinal tract cancers: insights from a Mendelian randomization study","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib124","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib125","article-title":"Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib126","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.semcancer.2025.01.007_bib127","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","article-title":"PD-1 and its ligands are important immune checkpoints in cancer","volume":"8","author":"Dong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2025.01.007_bib128","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2025.01.007_bib129","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.2147\/OTT.S152514","article-title":"Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies","author":"Togasaki","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.semcancer.2025.01.007_bib130","doi-asserted-by":"crossref","first-page":"37933","DOI":"10.1038\/srep37933","article-title":"The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2025.01.007_bib131","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","article-title":"Current status of immune checkpoint inhibitors for gastric cancer","volume":"23","author":"Kono","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib132","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2025.01.007_bib133","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2025.01.007_bib134","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00262-016-1936-0","article-title":"A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer","volume":"66","author":"Tao","year":"2017","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.semcancer.2025.01.007_bib135","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/jgh.14520","article-title":"Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer","volume":"34","author":"Wu","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib136","doi-asserted-by":"crossref","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2025.01.007_bib137","doi-asserted-by":"crossref","first-page":"90948","DOI":"10.18632\/oncotarget.18770","article-title":"PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2025.01.007_bib138","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1159\/000479231","article-title":"Protein expression of programmed death 1 ligand 1 and HER2 in gastric carcinoma","volume":"93","author":"Oki","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib139","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3389\/fphar.2018.01522","article-title":"Mutations defining patient cohorts with elevated PD-L1 expression in gastric cancer","volume":"9","author":"Menyh\u00e1rt","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib140","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib141","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib142","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/vaccines4030022","article-title":"The IL-8\/IL-8R axis: a double agent in tumor immune resistance","volume":"4","author":"David","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.semcancer.2025.01.007_bib143","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1359-6101(01)00016-8","article-title":"Interleukin-8 and human cancer biology","volume":"12","author":"Xie","year":"2001","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib144","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13547500600565677","article-title":"Serum levels of interleukin 1\u03b2, interleukin 8 and tumour necrosis factor \u03b1 as markers of gastric cancer","volume":"11","author":"Macri","year":"2006","journal-title":"Biomarkers"},{"key":"10.1016\/j.semcancer.2025.01.007_bib145","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41419-018-0988-9","article-title":"Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3\/mTOR-c-Myc signal axis","volume":"9","author":"Sun","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2025.01.007_bib146","first-page":"1","article-title":"CXCL9\/10\/11, a regulator of PD-L1 expression in gastric cancer","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib147","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10120-020-01079-z","article-title":"Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer","volume":"23","author":"Nakayama","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib148","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1172\/JCI80012","article-title":"Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade","volume":"125","author":"Buchbinder","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.semcancer.2025.01.007_bib149","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-065X.2008.00639.x","article-title":"CTLA-4: a key regulatory point in the control of autoimmune disease","volume":"223","author":"Scalapino","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib151","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1074-7613(00)80480-X","article-title":"Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement","volume":"4","author":"Linsley","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2025.01.007_bib152","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2025.01.007_bib153","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1074-7613(01)00259-X","article-title":"Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength","volume":"16","author":"Egen","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2025.01.007_bib154","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","article-title":"CTLA-4-Mediated inhibition of early events of T cell proliferation","volume":"162","author":"Brunner","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25^+ CD^+ regulatory T cells constitutively expressing cytotoxic lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib156","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG 3 (CD 223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib157","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/ijms19020379","article-title":"Galectin-3: one molecule for an alphabet of diseases, from A to Z","volume":"19","author":"Sciacchitano","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib158","first-page":"1369","article-title":"Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer","volume":"26","author":"Okada","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib159","first-page":"599","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy","volume":"41","author":"Dong","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib160","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/glycob\/cwq103","article-title":"Coordinated expression of galectin-3 and galectin-3-binding sites in malignant mammary tumors: implications for tumor metastasis","volume":"20","author":"De Oliveira","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib161","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.7150\/jca.26949","article-title":"Prognostic value of lymphocyte activation gene-3 (LAG-3) expression in esophageal squamous cell carcinoma","volume":"9","author":"Zhang","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib162","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.3390\/ijms22105282","article-title":"Understanding LAG-3 signaling","volume":"22","author":"Chocarro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib163","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1434467","article-title":"The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment","volume":"7","author":"Farhad","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib164","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/biom10050750","article-title":"Galectins as checkpoints of the immune system in cancers, their clinical relevance, and implication in clinical trials","volume":"10","author":"Compagno","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.semcancer.2025.01.007_bib165","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10555-007-9095-6","article-title":"Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway","volume":"26","author":"Nakahara","year":"2007","journal-title":"Cancer Metastas Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib166","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jss.2004.09.020","article-title":"K-ras mutation influences macroscopic features of gastric carcinoma","volume":"124","author":"Yashiro","year":"2005","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib167","doi-asserted-by":"crossref","first-page":"34922","DOI":"10.1074\/jbc.M312697200","article-title":"Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity","volume":"279","author":"Elad-Sfadia","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2025.01.007_bib168","doi-asserted-by":"crossref","first-page":"755","DOI":"10.12659\/MSM.892386","article-title":"Serum galectin-3 as a potential marker for gastric cancer","volume":"21","author":"Cheng","year":"2015","journal-title":"Med. Sci. Monit.: Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib169","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)","volume":"10","author":"Lv","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.semcancer.2025.01.007_bib170","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.3390\/diagnostics11122370","article-title":"Expression of immune checkpoints in malignant tumors: therapy targets and biomarkers for the gastric cancer prognosis","volume":"11","author":"Mansorunov","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.semcancer.2025.01.007_bib171","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib172","first-page":"2115","article-title":"Association between Tim\u20113 and Gal\u20119 expression and gastric cancer prognosis","volume":"40","author":"Wang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.semcancer.2025.01.007_bib173","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3892\/or.2016.4938","article-title":"TIM-3 promotes the metastasis of esophageal squamous cell carcinoma by targeting epithelial-mesenchymal transition via the Akt\/GSK-3\u03b2\/Snail signaling pathway","volume":"36","author":"Shan","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.semcancer.2025.01.007_bib174","first-page":"1461","article-title":"The effects of Tim\u20113 activation on T\u2011cells in gastric cancer progression","volume":"17","author":"Yu","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.semcancer.2025.01.007_bib175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081799","article-title":"Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer","volume":"8","author":"Jiang","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.semcancer.2025.01.007_bib176","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5152\/tjg.2017.16346","article-title":"Prognostic value of tumoral expression of galectin-9 in gastric cancer","volume":"28","author":"Choi","year":"2017","journal-title":"Turk. J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib177","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib178","article-title":"Therapeutic strategies targeting CD47-SIRP\u03b1 signaling pathway in gastrointestinal cancers treatment","author":"Che","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.semcancer.2025.01.007_bib179","first-page":"2017","article-title":"Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer","volume":"15","author":"Zhao","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.semcancer.2025.01.007_bib180","series-title":"Seminars in Oncology","first-page":"117","article-title":"Just eat it: A review of CD47 and SIRP-\u03b1 antagonism","author":"Oronsky","year":"2020"},{"key":"10.1016\/j.semcancer.2025.01.007_bib181","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.7150\/jca.31727","article-title":"Role of IDO and TDO in cancers and related diseases and the therapeutic implications","volume":"10","author":"Ye","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib182","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000492849","article-title":"The clinicopathological and prognostic significance of IDO1 expression in human solid tumors: evidence from a systematic review and meta-analysis","volume":"49","author":"Yu","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.semcancer.2025.01.007_bib183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1318-5","article-title":"A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis","volume":"38","author":"Xiang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/his.13504","article-title":"Expression of PD-L1, indoleamine 2, 3-dioxygenase and the immune microenvironment in gastric adenocarcinoma","volume":"73","author":"Patil","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib186","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10120-014-0440-5","article-title":"Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer","volume":"19","author":"Kim","year":"2016","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib187","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s10620-013-2837-0","article-title":"The correlation between the subsets of tumor infiltrating memory T cells and the expression of indoleamine 2, 3-dioxygenase in gastric cancer","volume":"58","author":"Zhang","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib188","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1007\/s13277-014-2126-3","article-title":"The subsets of dendritic cells and memory T cells correspond to indoleamine 2, 3-dioxygenase in stomach tumor microenvironment","volume":"35","author":"Li","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib189","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/glycob\/cwm049","article-title":"Siglec-15: an immune system Siglec conserved throughout vertebrate evolution","volume":"17","author":"Angata","year":"2007","journal-title":"Glycobiology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib190","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.7150\/jca.38747","article-title":"Integrative analysis of Siglec-15 mRNA in human cancers based on data mining","volume":"11","author":"Li","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib191","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib192","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12929-019-0610-1","article-title":"Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases","volume":"27","author":"Angata","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib193","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3390\/biology10111178","article-title":"Siglecs as therapeutic targets in cancer","volume":"10","author":"Lim","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib194","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/10409231003628015","article-title":"ADAM-17: the enzyme that does it all","volume":"45","author":"Gooz","year":"2010","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbrc.2009.01.013","article-title":"ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis","volume":"380","author":"G\u00f6\u0151z","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib196","first-page":"914","article-title":"ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways","volume":"43","author":"Li","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib197","doi-asserted-by":"crossref","first-page":"34529","DOI":"10.1074\/jbc.M113.488478","article-title":"A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3)","volume":"288","author":"M\u00f6ller-Hackbarth","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2025.01.007_bib198","doi-asserted-by":"crossref","first-page":"1744980","DOI":"10.1080\/2162402X.2020.1744980","article-title":"ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L) 1 inhibitor resistance","volume":"9","author":"Orme","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib199","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/medicina56070322","article-title":"Prognostic significance of ADAM17 for gastric cancer survival: a meta-analysis","volume":"56","author":"Ni","year":"2020","journal-title":"Medicina"},{"key":"10.1016\/j.semcancer.2025.01.007_bib200","first-page":"5941","article-title":"Clinical significance of ADAM10 and ADAM17 in gastric and colorectal cancers: A systematic review and meta-analysis","volume":"10","author":"Sun","year":"2017","journal-title":"Int. J. Clin. Exp. Med"},{"key":"10.1016\/j.semcancer.2025.01.007_bib201","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3390\/ijms21030922","article-title":"CD155: A multi-functional molecule in tumor progression","volume":"21","author":"Molfetta","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib202","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/eji.200737072","article-title":"The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens","volume":"37","author":"Maier","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib203","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.coi.2012.01.009","article-title":"Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer","volume":"24","author":"Chan","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib204","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/icb.2013.95","article-title":"DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins","volume":"92","author":"De Andrade","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib205","series-title":"Seminars in Cancer Biology","first-page":"189","article-title":"Tumor intrinsic and extrinsic immune functions of CD155","author":"O\u2019Donnell","year":"2020"},{"key":"10.1016\/j.semcancer.2025.01.007_bib206","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.str.2018.10.023","article-title":"Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155","volume":"27","author":"Deuss","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.semcancer.2025.01.007_bib207","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.5858\/arpa.2016-0580-OA","article-title":"Validation of an immunohistochemistry assay for detection of CD155, the poliovirus receptor, in malignant gliomas","volume":"141","author":"Chandramohan","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib208","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1172\/JCI98769","article-title":"CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms","volume":"128","author":"Li","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.semcancer.2025.01.007_bib209","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","article-title":"CD155T\/TIGIT signaling regulates CD8+\u2009T-cell metabolism and promotes tumor progression in human gastric cancer","volume":"77","author":"He","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib210","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.608404","article-title":"CD155 overexpression correlates with poor prognosis in primary small cell carcinoma of the esophagus","volume":"7","author":"Zhao","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib211","article-title":"CD155-prognostic and immunotherapeutic implications based on multiple analyses of databases across 33 human cancers","volume":"20","author":"Zhang","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.semcancer.2025.01.007_bib212","doi-asserted-by":"crossref","first-page":"3948928","DOI":"10.1155\/2020\/3948928","article-title":"Overexpression of an immune checkpoint (CD155) in breast cancer associated with prognostic significance and exhausted tumor-infiltrating lymphocytes: a cohort study","volume":"2020","author":"Li","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib213","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108884","article-title":"CD155 expression and its prognostic value in postoperative patients with breast cancer","volume":"115","author":"Yong","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.semcancer.2025.01.007_bib214","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/excr.1999.4610","article-title":"Redefined nomenclature for members of the carcinoembryonic antigen family","volume":"252","author":"Beauchemin","year":"1999","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib215","article-title":"CEACAM1 as a multi-purpose target for cancer immunotherapy","volume":"6","author":"Dankner","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib216","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2025.01.007_bib217","doi-asserted-by":"crossref","first-page":"7169081","DOI":"10.1155\/2018\/7169081","article-title":"On the dual role of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in human malignancies","volume":"2018","author":"Calinescu","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib218","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1097-2765(00)80426-8","article-title":"CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor","volume":"5","author":"Erg\u00fcn","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib219","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.619765","article-title":"TIM-3 and CEACAM1 are prognostic factors in head and neck squamous cell carcinoma","volume":"8","author":"Yang","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib220","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2002.05.033","article-title":"CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease","volume":"20","author":"Thies","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib221","first-page":"249","article-title":"Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases","volume":"29","author":"Th\u00f6m","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib222","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1038\/s41467-020-20260-7","article-title":"An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib223","doi-asserted-by":"crossref","first-page":"12702","DOI":"10.1038\/s41598-019-49230-w","article-title":"Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer","volume":"9","author":"Takeuchi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2025.01.007_bib224","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12935-018-0668-y","article-title":"Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.semcancer.2025.01.007_bib225","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijsu.2018.06.033","article-title":"Clinical characteristics and prognostic significance of galectins for patients with gastric cancer: a meta-analysis","volume":"56","author":"Long","year":"2018","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.semcancer.2025.01.007_bib226","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.prp.2014.03.014","article-title":"Expression of carcinoembryonic antigen-related cell adhesion molecule 1(CEACAM1) and its correlation with angiogenesis in gastric cancer","volume":"210","author":"Shi","year":"2014","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.semcancer.2025.01.007_bib227","doi-asserted-by":"crossref","DOI":"10.4081\/ejh.2021.3174","article-title":"Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters","volume":"65","author":"Quirino","year":"2021","journal-title":"Eur. J. Histochem.: EJH"},{"key":"10.1016\/j.semcancer.2025.01.007_bib228","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000507798","article-title":"Immunotherapy in gastrointestinal cancers","volume":"36","author":"G\u00fcthle","year":"2020","journal-title":"Visc. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib229","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1517\/13543784.2013.793307","article-title":"Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives","volume":"22","author":"Hernandez-Alcoceba","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.semcancer.2025.01.007_bib230","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib231","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1158\/0008-5472.CAN-12-0721","article-title":"IL-10 directly activates and expands tumor-resident CD8+\u2009T cells without de novo infiltration from secondary lymphoid organs","volume":"72","author":"Emmerich","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib232","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, antitumor activity, and immune activation of pegylated recombinant human Interleukin-10 (AM0010) in patients with advanced solid tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib233","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","article-title":"Targeting tumors with IL-10 prevents dendritic cell-mediated CD8+ T cell apoptosis","volume":"35","author":"Qiao","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib234","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4509","article-title":"Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)","author":"Tannir","year":"2018","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib235","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ijc.33556","article-title":"Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: final results of cohorts A, G, H and I of IVY Phase I study","volume":"149","author":"Tannir","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib236","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-020-17811-3","article-title":"Selective inhibition of TGF-\u03b21 produced by GARP-expressing Tregs overcomes resistance to PD-1\/PD-L1 blockade in cancer","volume":"11","author":"de Streel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib237","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/ijc.31730","article-title":"Dual TGF-\u03b2 and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+\u2009T cell response in esophageal squamous cell carcinoma","volume":"143","author":"Chen","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib238","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cells8040320","article-title":"Combined inhibition of TGF-\u03b2 signaling and the PD-L1 immune checkpoint is differentially effective in tumor models","volume":"8","author":"Sow","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2025.01.007_bib239","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1007\/s13277-013-1472-x","article-title":"Transforming growth factor-beta1 signaling blockade attenuates gastric cancer cell-induced peritoneal mesothelial cell fibrosis and alleviates peritoneal dissemination both in vitro and in vivo","volume":"35","author":"Miao","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib240","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.18632\/aging.102329","article-title":"TGF-\u03b2 receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-\u03b2\/SMAD4 signaling pathway","volume":"11","author":"Yang","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.semcancer.2025.01.007_bib241","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10120-017-0726-5","article-title":"Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: inhibition of growth and fibrosis by tranilast","volume":"21","author":"Saito","year":"2018","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib242","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.bjc.6605561","article-title":"Inhibitory effect of a TGF\u03b2 receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells","volume":"102","author":"Shinto","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib243","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1158\/0008-5472.CAN-08-0449","article-title":"Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib244","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/s41417-023-00632-z","article-title":"Production of an interleukin-10 blocking antibody by genetically engineered macrophages increases cancer cell death in human gastrointestinal tumor slice cultures","volume":"30","author":"Labadie","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.semcancer.2025.01.007_bib245","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib246","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/curroncol29030131","article-title":"Immunotherapy in gastric cancer","volume":"29","author":"H\u00f6gner","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib247","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.7150\/jca.31755","article-title":"Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancer","volume":"10","author":"Yu","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib248","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1078-0432.CCR-16-1163","article-title":"PD-1\/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors","volume":"23","author":"Seifert","year":"2017","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib249","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib250","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib251","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim. Et. Biophys. Acta (BBA)-Rev. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib252","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2025.01.007_bib253","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib254","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib255","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.annonc.2020.11.018","article-title":"Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy","volume":"32","author":"Sznol","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib256","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-17-0025","article-title":"Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced\/metastatic gastric or gastroesophageal junction cancer","volume":"23","author":"Bang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib257","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/1078-0432.CCR-19-2443","article-title":"Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma","volume":"26","author":"Kelly","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib258","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.4010","article-title":"CheckMate-032: phase I\/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A\/M) gastric cancer (GC)","author":"Janjigian","year":"2016","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib259","author":"Moehler","year":"2016","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib260","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919867522","article-title":"Late-line treatment in metastatic gastric cancer: today and tomorrow","volume":"11","author":"Smyth","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib261","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/cancers14041054","article-title":"The new era of immunotherapy in gastric cancer","volume":"14","author":"Takei","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2025.01.007_bib262","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4012","article-title":"KEYNOTE-059 cohort 2: safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer","author":"Bang","year":"2017","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib263","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib264","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib265","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib266","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4031","article-title":"Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: updated results from a multicenter, open label phase II trial","author":"Shen","year":"2019","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib267","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07251-z","article-title":"Safety and efficacy of sintilimab combined with oxaliplatin\/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib268","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.211","article-title":"Sintilimab plus oxaliplatin\/capecitabine (CapeOx) as neoadjuvant therapy in patients with locally advanced, resectable gastric (G)\/esophagogastric junction (GEJ) adenocarcinoma","author":"Jiang","year":"2021","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib269","doi-asserted-by":"crossref","first-page":"S929","DOI":"10.1016\/j.annonc.2020.08.2004","article-title":"1498TiP A multi-center, randomized, open-label, phase III study of sintilimab+\u2009ramucirumab as 1st-line treatment for advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (ORIENT-106)","volume":"31","author":"Xu","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib270","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432","volume":"30","author":"Wang","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib271","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1158\/1078-0432.CCR-19-3561","article-title":"Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric\/gastroesophageal junction adenocarcinoma","volume":"26","author":"Xu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib272","doi-asserted-by":"crossref","first-page":"S909","DOI":"10.1016\/j.annonc.2020.08.1951","article-title":"1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC\/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study","volume":"31","author":"Shen","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib273","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT120","article-title":"Abstract CT120: AK104, a PD-1\/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in a phase Ib trial in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer","volume":"80","author":"Ji","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib274","author":"Rha","year":"2020","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib275","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","article-title":"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib276","unstructured":"Fa.D.A. (FDA), FDA Approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma- FDA amends pembrolizumab\u2019s gastric cancer indication, in: FDA (Ed.), 2021."},{"key":"10.1016\/j.semcancer.2025.01.007_bib277","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(20)30326-0","article-title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22\u201305): A single-arm, phase 1b\u20132 trial","volume":"21","author":"Catenacci","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib278","unstructured":"A. Krassowska, MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer, in: I. MacroGenics (Ed.), 2020."},{"key":"10.1016\/j.semcancer.2025.01.007_bib279","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1078-0432.CCR-20-3559","article-title":"Multicenter phase I\/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer","volume":"27","author":"Nakajima","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib280","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.129","article-title":"Phase I\/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study)","author":"Hara","year":"2019","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib281","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib282","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(20)30271-0","article-title":"Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial","volume":"21","author":"Kawazoe","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib283","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study","author":"Villanueva","year":"2021","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib284","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejca.2020.06.007","article-title":"Ramucirumab and durvalumab for previously treated, advanced non\u2013small-cell lung cancer, gastric\/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia\/b study (JVDJ)","volume":"137","author":"Bang","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib285","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib286","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10120-020-01058-4","article-title":"Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer","volume":"23","author":"Sasaki","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib287","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","article-title":"Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment","volume":"25","author":"Sato","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib288","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/labinvest.2013.8","article-title":"Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment","volume":"93","author":"Dodbiba","year":"2013","journal-title":"Lab. Investig."},{"key":"10.1016\/j.semcancer.2025.01.007_bib289","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2025.01.007_bib290","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2025.01.007_bib291","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib292","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1251539","article-title":"CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: from bench to bedside","volume":"5","author":"Zhang","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2025.01.007_bib293","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jnci\/djy134","article-title":"Claudin18. 2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer","volume":"111","author":"Jiang","year":"2019","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2025.01.007_bib294","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2509","article-title":"Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma","author":"Zhan","year":"2019","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib295","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00280-018-3670-0","article-title":"Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment","volume":"82","author":"Tao","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib296","article-title":"Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer","volume":"13","author":"Kim","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.semcancer.2025.01.007_bib297","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s13238-017-0384-8","article-title":"Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo","volume":"9","author":"Song","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.semcancer.2025.01.007_bib298","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-020-0183-x","article-title":"PSCA is a target of chimeric antigen receptor T cells in gastric cancer","volume":"8","author":"Wu","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.semcancer.2025.01.007_bib299","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0704-y","article-title":"Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer","volume":"12","author":"Lv","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib300","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1111\/cas.14612","article-title":"Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced \u03b3\u03b4T cells against lung cancer cells","volume":"111","author":"Ichiki","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2025.01.007_bib301","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3748\/wjg.v26.i4.424","article-title":"Cancer\/testis antigen, Kita-Kyushu lung cancer antigen-1 and ABCD stratification for diagnosing gastric cancers","volume":"26","author":"Shida","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0678-x","article-title":"Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1","volume":"7","author":"Marcinkowski","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib303","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3389\/fimmu.2019.01321","article-title":"L-selectin enhanced T cells improve the efficacy of cancer immunotherapy","volume":"10","author":"Watson","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib304","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.7150\/jca.18946","article-title":"Phase II trial of adjuvant immunotherapy with autologous tumor-derived Gp96 vaccination in patients with gastric cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib305","article-title":"MAGE-3 peptide amphiphile micelle vaccine promote anti-tumor immunity in mice with stomach cancer","author":"Windberg","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.semcancer.2025.01.007_bib306","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10120-013-0258-6","article-title":"Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer","volume":"17","author":"Ishikawa","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib307","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2025.01.007_bib308","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2025.01.007_bib309","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib311","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","article-title":"The advent of oncolytic virotherapy in oncology: The Rigvir\u00ae story","volume":"837","author":"Alberts","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib312","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122319","article-title":"Potentiating cancer vaccination by adjuvant-loaded cryo-shocked tumor cells","volume":"302","author":"Chen","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.semcancer.2025.01.007_bib313","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc3013","article-title":"Cryo-shocked cancer cells for targeted drug delivery and vaccination","volume":"6","author":"Ci","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.semcancer.2025.01.007_bib314","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3844\/ajisp.2009.65.83","article-title":"Cytokines as adjuvants for vaccine and cellular therapies for cancer","volume":"5","author":"Capitini","year":"2009","journal-title":"Am. J. Immunol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib315","first-page":"261","article-title":"Cytokines as potential vaccine adjuvants","author":"Nohria","year":"1995","journal-title":"Cytokines Treat. Infect. Dis.: Options Modul. Host Def."},{"key":"10.1016\/j.semcancer.2025.01.007_bib316","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-021-01106-x","article-title":"Immune checkpoint inhibitors in the aged","volume":"23","author":"Isaacs","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.semcancer.2025.01.007_bib317","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis","volume":"6","author":"Elias","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib318","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jgo.2019.05.013","article-title":"Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: a meta-analysis","volume":"11","author":"Kasherman","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib319","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.semcancer.2025.01.007_bib320","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00262-020-02779-2","article-title":"Efficacy of immune checkpoint inhibitors in elderly patients aged\u2265\u200975 years","volume":"70","author":"Petrelli","year":"2021","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.semcancer.2025.01.007_bib321","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jgo.2018.07.015","article-title":"The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population","volume":"10","author":"Sattar","year":"2019","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib322","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2025.01.007_bib323","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.10009","article-title":"Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)","author":"Friedman","year":"2016","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.01.007_bib324","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00262-019-02298-9","article-title":"Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma","volume":"68","author":"Leroy","year":"2019","journal-title":"Cancer Immunol. Immunother."}],"updated-by":[{"DOI":"10.1016\/j.semcancer.2025.11.010","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25000161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25000161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T01:35:16Z","timestamp":1741743316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X25000161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":324,"alternative-id":["S1044579X25000161"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.01.007","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}